vimarsana.com
Home
Live Updates
FDA Approves Genentech's Columvi, the First and Only Bispeci
FDA Approves Genentech's Columvi, the First and Only Bispeci
FDA Approves Genentech's Columvi, the First and Only Bispecific Antibody With a Fixed-Duration Treatment for People With Relapsed or Refractory Diffuse Large B-cell Lymphoma | Business
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Jun 15, 2023--
Related Keywords
South San Francisco ,
California ,
United States ,
Sweden ,
Canada ,
Swedish ,
Krish Patel ,
Loren Kalm ,
Cem Mangir ,
Lindsey Mathias ,
Informationandmedication Guideor ,
Bruno Eschli ,
Levi Garraway ,
Genentech Access Solutions ,
Drug Administration ,
Global Product Development ,
Roche Group ,
Genentech ,
Swedish Cancer Institute In Seattle ,
Lymphoma Program ,
Global Product ,
Swedish Cancer Institute ,
Columvi Phase ,
New England Journal ,
European Medicines Agency ,
Medicinal Products ,
Human Use ,
Genentech Access ,
Largeb Cell Lymphoma Arising ,
Cytokine Release Syndrome ,
Columvi Patient Wallet Card ,
Important Safety Information ,
Serious Side Effects ,
Prescribing Information ,
Medication Guide ,
Prescribing Informationandmedication Guideor ,
Blood Cell Counts ,
Prescribing Informationand ,
Important Safety ,
Media Contact ,
Business Wire ,
Business ,